1 Excised outside-out patches from HEK293 cells stably transfected with the human (h) 5-HT 3A receptor cDNA were used to determine the eects of cannabinoid receptor ligands on the 5-HTinduced current using the patch clamp technique. In addition, binding studies with radioligands for 5-HT 3 as well as for cannabinoid CB 1 and CB 2 receptors were carried out. 
Introduction
It is generally accepted that the eect of D 9 -THC and other exogenous and endogenous cannabinoids are mediated via cannabinoid receptors. Two cannabinoid receptor subtypes CB 1 and CB 2 have so far been identi®ed, characterized and cloned (for reviews, see Pertwee, 1997; 1999; 2000; Ameri, 1999) . The CB 1 receptor occurs in brain and nervous tissue (Herkenham et al., 1990; Matsuda et al., 1990; Mailleux et al., 1992) whereas the CB 2 receptor is expressed mainly extraneuronally by immune cells (Munro et al., 1993) . Accordingly, the eects of cannabinoids in the nervous system are generally believed to be mediated almost exclusively by CB 1 receptors. Cannabinoid receptor agonists do not only exert psychotropic eects (see reviews quoted above and Abood & Martin, 1992) , but they also play a role in the control of pain and emesis (reviews quoted above and splice variants are not qualitatively modi®ed (Davies et al., 1999; BruÈ ss et al., 2000; Brady et al., 2001) ; at most, minor dierences in anity or potency of 5-HT 3 receptor ligands may exist (Dubin et al., 1999) .
According to the involvement of both cannabinoid (for references, see above) and 5-HT 3 receptors (reviews quoted above and Aapro, 1991; Mitchelson, 1992; Karim et al., 1996; Voog et al., 2000; Simpson et al., 2000) in pain and emesis it is conceivable that cannabinoids act not only via CB 1 receptors, but also at an allosteric modulatory site of the 5-HT 3 receptor. This possibility has been supported by experiments on the rat nodose ganglion neurone (Fan, 1995) which suggested that neuronal cannabinoid receptors interact with the 5-HT 3 receptor ion channel and that the latter may be a direct target of cannabinoid receptor agonists. Cannabinoid receptor-independent eects of cannabinoids, in particular the endogenous agonist anandamide, have been reported for other ion channels such as vanilloid VR1 receptors (Zygmunt et al., 1999; Malinowska et al., 2001) , TASK-1 K + channels (Maingret et al., 2001) , Shaker-related Kv1.2 K + channels (Poling et al., 1996) and T-type calcium channels (Chemin et al., 2001) .
In view of the putative physiological and therapeutic signi®cance in humans, the aim of the present study was to clarify whether cannabinoids directly inhibit 5-HT-induced currents through the h5-HT 3A receptor channels and, if so, to analyse the underlying site and mechanism of action. The experiments were carried out on HEK 293 cells stably transfected with the h5-HT 3A receptor cDNA. The patchclamp technique on excised outside-out patches and standard radioligand binding were used. The recombinant homomeric h5-HT 3A receptor channels in this system have previously been characterized . Preliminary results of the present investigation have been published elsewhere in abstract form (Barann et al., 2001; Godlewski et al., 2002) .
Methods

Cell culture
HEK 293 cells were grown as monolayers on culture plates (Nunc) in DMEM Nutrient Mix F12 (1 : 1; v v 71 ) medium containing 10% heat inactivated foetal calf serum, penicillin (100 IU ml 71 ), streptomycin (100 mg ml 71 ), geneticine (0.75 mg ml
71
) and glutamine (292 mg ml
). The cells were cultured at 378C in a humidi®ed atmosphere (5% CO 2 ). Two days before an experiment cells were subcultured in monodishes (NUNC, 35 mm diameter).
Transfection
For stable transfection 20% con¯uent HEK 293 cells were transfected by the modi®ed calcium phosphate method with the h5-HT 3A receptor cDNA (according to Chen & Okayama, 1987) subcloned into the mammalian expression vector pcDNA3 (Invitrogen) under control of the human cytomegalo virus promoter. Two days after transfection, stably transfected cells were selected by the addition of geneticine (800 mg ml
71
) to the culture medium. The medium was changed every 2 days. After occurrence of single cell colonies these were separated by usage of cloning cylinders 
Electrophysiology
In a standard voltage-clamp experiment, 30 mM 5-HT was applied for 1 ± 2 s at 7100 mV on an excised outside-out patch using a fast solution exchange system (exchange time 1 ± 2 ms; patch resistance: 1 ± 10 gigaohm; Liu & Dilger, 1991) . The external solution applied on the patch was of the following composition (mM): NaCl 150, KCl 5.6, CaCl 2 1.8, MgCl 2 1.0, HEPES 10, pH 7.4. Patch pipettes with resistances of 3 ± 6 MO were ®lled with`intracellular' solution containing (mM) KCl 140, EGTA 10, MgCl 2 5, HEPES 10, pH 7.4. For current measurements, we used a patch-clamp ampli®er (EPC-7; List Electronic, Darmstadt, Germany) with the output ®lter set at 1 kHz and pClamp software (Axon Instruments, Foster City, CA, U.S.A.). The sampling rate varied between 200 and 2000 Hz; within this range, no signi®cant dierences were seen with regard to ®tted time constants. The drug application system was equipped with inert materials like te¯on tubing and glass to avoid losses of lipophilic drugs.
Radioligand binding experiments
All steps of the preparation procedure were performed on ice. Freshly harvested HEK 293 cells (parental or stably transfected with the human 5-HT 3A cDNA) were suspended in 40 ml of a buer solution containing (mM): HEPES-Na + 5, EGTA 0.5, MgCl 2 0.5, ascorbic acid 0.1, and phenylmethylsulphonyl¯uoride 0.3, pH 7.4 (buer I), and homogenized using a glass-Te¯on homogenizer (3630 s). The homogenates were centrifuged (5 min, 12006g, 48C). The supernatant was poured o, diluted to 420 ml with buer I and recentrifuged (20 min, 40,0006g, 48C) . The pellet was washed twice, resuspended in buer II (mM): (HEPES-Na+ 5, EGTA 0.5, MgCl 2 0.5, ascorbic acid 0.1, pH 7.4), homogenized, and diluted to give a protein concentration of about 1 mg ml 71 and stored at 7808C until use. Before the membranes were added to the incubation assay, they were centrifuged (20 min, 40,0006g, 48C), resuspended in the incubation buer (buer II), homogenized by ultrasonication and diluted to a ®nal protein concentration of about 0.6 mg ml
71
. A 400 ml aliquot of membranes was incubated for 60 min with [ Competition studies were carried out using [ 3 H]-GR65630 (10 nM) and up to 13 dierent concentrations of the unlabelled ligand under study, ranging from 1 nM up to 100 mM. Protein concentration was measured by the method of Bradford (1976) using bovine serum albumin as standard.
To test parental HEK 293 cells for the expression of endogenous CB 1 -/CB 2 -receptors, radioligand binding was performed as described above with 5 nM [ 3 H]-CP55940 and speci®c binding was determined by competition with 3 mM unlabelled CP55,940.
Data analysis
The currents were digitized with an interface (Digidata 1200, Axon Instruments) and stored on an IBM 586-compatible PC. Data analysis was performed with pClamp R 7 software (Axon). Graph Pad Prism R software (Graph Pad, CA, U.S.A.) was used to create graphics. The concentration-response curves for 5-HT were ®tted by the Hill equation, i=c n /(c n +EC n 50 ): i is the immediate peak current as fraction of the maximal (control) current, c is the 5-HT concentration, n is the Hill coecient and EC 50 is the 5-HT concentration inducing the half-maximal eect. This equation was analogously applied to determine the cannabinoid inhibition of the 5-HT response. Solutions 5-HT solutions were prepared daily from 50 mM aqueous stocks (stored at 7208C). Cannabinoid solutions were prepared daily from 10 mM stocks in DMSO (stored at 7208C; ®nal DMSO concentration 40.01%). MDL72222 was dissolved daily in methanesulphonic acid (®nal concentration 40.001%). The vehicles in the concentrations used, had no eect on radioligand binding or current response.
Drugs used
3-Tropanyl-3,5-dichlorobenzoate (MDL72222) was from RBI (Natick, U.S.A.). (N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbox-amide hydrochloride (SR141716A) from Sano® (Montpellier, France); 5-hydroxytryptamine creatine sulphate (5-HT), ([2- methyl-1-propyl-1H-indol-3-yl]-1-naphthalen-ylmethanone) (JWH-015), D 9 -tetrahydrocannabinol (D 9 -THC), (S)-(7)-[2,3- dihydro-5-methyl-3-(4-morpholinyl methyl) pyrrolo [1,2,3- de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone-mesylate (WIN55,212-3) were obtained from Sigma (Munich, Germany); (all Z)-N-(2-hydroxyethyl)-5,8,11,14-eicosa-tetraenamide (anand- amide), (7)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]- trans-4-(3-hydroxypropyl)cyclohexanol (CP55940) and ((R)- (+)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone me- sylate (WIN55,212-2) were obtained from Tocris/Biotrend (Cologne, Germany); [6-methoxy-2-(4-methoxyphenyl)ben- zo[b]furane-3-yl][4-cyanophenyl]methanone(LY320135) was a present from Lilly, Indianapolis, Indiana, U.S.A.; [ 3 H](7)- cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hy- droxypropyl) cyclohexanol ([ 3 H]-CP55940 speci®c activity 101 Ci mmol 71 ) from NEN, Zaventem, Belgium; [ 3 H]-(3-(5- methyl-1H-imidazol-4-yl)-1-(1-methyl-1H-indol-3-yl)-1-propa- none) ([
Results
Effects of cannabinoid receptor ligands on 5-HT-induced currents
In excised outside-out patches of HEK 293 cells stably transfected with h5-HT 3A receptors, 5-HT (present for 1 ± 2 s) evoked currents in a concentration dependent manner ( Figure  1 ; EC 50 =8.9 mM, Hill coecient=1.4; n=3 ± 6; see also Figure 2 for original traces).
In most of the experiments in which the eects of cannabinoid receptor ligands were determined, 5-HT was applied at a standard concentration of 30 mM and the cannabinoids were present 3 min before and during (and after) the 5-HT stimulus. In experiments with all cannabinoid receptor ligands investigated (at concentrations approximately corresponding to the respective EC 50 values n=3 ± 6), this preexposure time has been shown to be sucient to obtain an equilibrium eect (results not shown).
WIN55,212-2 inhibited the 5-HT-induced current ( Figure  2 ). This inhibition was concentration-dependent ( Figure 3a) and not voltage-dependent between 7100 mV and +100 mV (n=3, not shown). The CB 1 receptor antagonist SR141716A at the concentration of 1 mM did not modify the WIN55,212-2-induced inhibition (Figure 3a) . In contrast to WIN55,212-2, its enantiomer WIN55,212-3 even at the high concentration of 1 mM did not change the 5-HT-evoked current ( Figures 2  and 3a) ; at this concentration WIN55,212-2 almost abolished the 5-HT-induced current.
The cannabinoid receptor agonists D
9
-THC, JWH-015 and CP55940, the endogenous cannabinoid receptor agonist anandamide and the CB 1 receptor antagonist LY320135 In a further series of experiments, the eect of WIN55,212-2 on the concentration-response curve of 5-HT was determined. When applied at a concentration (300 nM) three times higher than that which produced half maximal inhibition of 5-HT-induced currents through h5-HT 3A receptors (compare Table 1 ), WIN55,212-2 did not change the EC 50 value of 5-HT in stimulating currents (8.9 versus 9.3 mM), but reduced the maximum of the 5-HT concentration-response curve (Figure 1) .
Finally the eect of 1 mM WIN55,212-2 on the 5-HTevoked current was studied at dierent time schedules of application (Figure 4) . Under the standard conditions, i.e. application of the drug 3 min before, during (and after) the 2 s stimulation with 5-HT, WIN55,212-2 produced an almost complete inhibition of current (lower left panel). Virtually the same degree of inhibition of 5-HT-induced current was obtained when the cannabinoid was present only 3 min before (and after), but not during stimulation with 5-HT (lower right panel). In contrast, application of the drug exclusively during the 2 s 5-HT pulse (upper right panel) was ineective. Analogous results were obtained with all cannabinoids investigated (at least n=3 in each series of experiments; results not shown).
Radioligand binding experiments
In contrast to the clear-cut speci®c binding of the 5-HT 3 receptor radioligand [ 
Discussion
The aim of the present study was to examine whether cannabinoid receptor ligands produce an inhibition of currents through recombinant homomeric h5-HT 3A receptors by an action at the receptor itself. The possibility that cannabinoid receptor agonists might directly in¯uence the 5-HT 3 receptor was derived from an electrophysiological study on rat nodose ganglion neurones (Fan, 1995) . In that investigation on whole cells, D 9 -THC, anandamide, WIN55,212-2, CP55940 and CP56667 inhibited the 5-HTevoked current. CP55940 and CP56667 are enantiomers, the latter compound being clearly less potent (by a factor of more than 10). The anandamide-induced inhibition was noncompetitive and was not aected by nonhydrolyzable cAMP and GTP analogues. These results were compatible with an action at the 5-HT 3 receptor itself, but in view of the putative presence of CB 1 receptors in addition to 5-HT 3 receptors in these cells, an interaction of both receptors could not be ruled out, in particular because interaction experiments with cannabinoid receptor antagonists were not performed.
The present investigation with cannabinoid receptor ligands on excised outside-out patches from HEK 293 cells expressing the human 5-HT 3A receptor, which also revealed an inhibition of 5-HT-induced currents, provides an answer to this open question. The rank order of potencies of cannabinoids in inhibiting h5-HT 3A receptors was clearly dierent from the anities of these drugs for hCB 1 or hCB 2 receptors (Table 1) , arguing against an involvement of the latter receptor types in this eect. This view is strongly supported by our ®nding that the selective CB 1 receptor antagonist SR141716A (Thomas et al., 1990) did not antagonize the inhibitory eect of WIN55,212-2 on the 5-HT-evoked current (Figure 3a) . In addition, the inhibition was stereoselective, which argues against the possibility that the inhibitory eect of the cannabinoids might be exclusively related to their lipophilicity, although a hydrophobic component in the mechanism of action cannot be excluded.
The eect of WIN55,212-2 on the concentration-response curve of 5-HT was typical for a non-competitive inhibitor. This makes a direct interaction with the agonist recognition site unlikely. This conclusion is supported by our radioligand binding experiments, since (1) three cannabinoid receptor agonists did not reduce the speci®c binding of a selective 5-HT 3A receptor ligand and (2) CP55940 did not alter the concentration-dependent inhibition of speci®c [ Since, furthermore, there was no speci®c binding of the CB 1 receptor ligand [ 3 H]-SR141716A (Rinaldi-Carmona et al., 1996; for reviews, see Pertwee, 1997; 2000) nor of the CB 1 /CB 2 receptor ligand [ 3 H]-CP55940 (for reviews, see Pertwee, 1997; 2000) to membranes of HEK 293 cells, the possibility that such receptors are expressed in the cell membrane of HEK 293 cells is excluded. The most plausible alternative is that WIN55,212-2 and the other cannabinoid receptor agonists act at a particular modulatory site of the h5-HT 3A receptor itself. Since the possibility that this site may modify ligand association to, or dissociation from, the 5-HT recognition site of the h5-HT 3A receptor was excluded by our binding experiments, the alternative was considered that cannabinoid binding to this site may inhibit currents through the receptor pore, e.g., either by an open channel block or by an inhibitory allosteric interaction leading to a change in channel gating or closure mechanisms.
Evidence as to whether or not the drugs produce an open channel block could be derived from experiments in which the time schedule of drug application was modi®ed and in which the voltage-dependence of the inhibitory eect of WIN55,212-2 was investigated: obviously, the site involved in the inhibition of channel function is not easily accessible, as Figure 1 for the eect of WIN55,312-2); the values shown in the table were determined from the concentrationresponse curves shown in Figure 3a ,b. K i values for inhibition of radioligand binding to human cannabinoid receptors in membrane preparations were taken from the literature: *Tao & Abood, 1998; {Showalter et al., 1996; {{Felder et al., 1998. can be derived from the rather long equilibrium period of 3 min before stimulation which is necessary to establish the eect and from the failure of the drugs to produce an inhibition when applied exclusively during, but not before, stimulation with 5-HT. However, a location in transmembrane or cytosolic domains of the receptor protein rather than within the open pore would be compatible with the necessity of the presence of the cannabinoids before stimulation at such an equilibrium time and with the lack of voltage-dependence of the WIN55,212-2-induced inhibition of 5-HT-evoked current.
The location in the transmembrane domain or its immediate proximity would make this site easily accessible to the endogenous ligand anandamide (Devane et al., 1992; Fride & Mechoulam, 1993) ; this compound is produced by enzymatic cleavage from membrane lipid precursors (reviewed by Piomelli et al., 2000; Porter & Felder, 2001 ) and it inhibits 5-HT-evoked currents with remarkable potency (Table 1) . It is an attractive hypothesis to postulate that the 5-HT 3 receptor is endowed with a motif which is recognized not only by all CB 1 and CB 2 receptor agonists, but also by the CB 1 receptor antagonist LY320135 (Felder et al., 1998) . This drug mimics the inhibitory eect of the cannabinoid receptor agonists at the allosteric modulatory site of the 5-HT 3 receptor.
At this modulatory site which, thus, shares pharmacological properties with hCB 1 and hCB 2 receptors without being identical with them, the phytocannabinoid D
9
-THC acts at a potency similar to its anity for hCB 1 and hCB 2 receptors, whereas synthetic cannabinoids are less potent at this site compared to their anity for hCB 1 or hCB 2 or both receptors (Table 1) . This property of D 9 THC is compatible with the view that the inhibition of h5-HT 3A receptor function found here may contribute to the behavioural eects of this compound.
As already mentioned, the potency of the endogenous ligand anandamide at this site is rather high (Table 1) . Accordingly, it is conceivable that the allosteric site of the h5-HT 3A receptor may be tonically activated by anandamide and, hence may play a physiological role by mediating a regulatory eect on the functional state of the 5-HT 3 receptor. The allosteric modulatory site of the 5-HT 3 receptor may be considered as a target for a new class of drugs used, e.g., for the control of pain and emesis.
A prerequisite for such eects is that the cannabinoid receptor-independent inhibitory eect of cannabinoids is also operative in vivo. Evidence for this can be derived from preliminary results obtained in a study which has been performed in anaesthetized rats pretreated with the CB 1 receptor antagonist SR141716A (Godlewski et al., 2002) . In such animals, activation of the 5-HT 3 receptors on cardiac aerent vagal nerves by bolus injection of phenylbiguanide induced the Bezold-Jarisch re¯ex, i.e. a decrease in heart rate.
This eect was inhibited by CP55940 and WIN55,212-2 but not by WIN55,212-3, whereas the vanilloid VR1 receptormediated Bezold-Jarisch re¯ex was unaected.
Taken together, the present patch-clamp study on excised outside-out patches of HEK 293 cells expressing recombinant homomeric 5-HT 3A receptors revealed that cannabinoid receptor ligands including the phytocannabinoid D 9 THC, the endocannabinoid anandamide and the CB 1 receptor antagonist LY320135 inhibit the 5-HT-induced currents. The synthetic cannabinoid WIN55,212-2, but not its enantiomer WIN55,212-3, shared the inhibitory eect. Since radioligand binding experiments excluded both the involvement of CB 1 and CB 2 receptors in this eect and an action of the cannabinoids at the 5-HT recognition site of the 5-HT 3 receptor, the most plausible site and mechanism of action is a direct modulatory eect on the h5-HT 3A receptor channel via an allosteric site.
